Dosing for BELSOMRA® (suvorexant)
Find the right dose of BELSOMRA for each patient.
For appropriate adult patients with insomnia who have trouble falling asleep and/or staying asleep.
When used with moderate CYP3A inhibitors, the recommended dosage of BELSOMRA is 5 mg taken no more than once per night (the dose generally should not exceed 10 mg). BELSOMRA is not recommended for use with strong CYP3A inhibitors.
- Use the lowest dose that is effective for the patient
- Patients should take BELSOMRA no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening
- Time to effect of BELSOMRA may be delayed if taken with or soon after a meal
- The recommended dose of BELSOMRA is 10 mg taken no more than once per night
- The dose can be increased if well tolerated but not effective enough
- The maximum recommended dose of BELSOMRA is 20 mg taken no more than once per night
Additional dosing information
- Exposure to BELSOMRA is increased in obese compared to non-obese patients, and in women compared to men. Particularly in obese women, the increased risk of exposure-related adverse effects should be considered before increasing the dose
- When BELSOMRA is combined with other CNS depressant drugs, dosage reduction of BELSOMRA and/or the other drug(s) may be necessary because of potentially additive effects
- No dose adjustment is required in patients with mild and moderate hepatic impairment. BELSOMRA has not been studied in patients with severe hepatic impairment and is not recommended for these patients
Inform your patients about the importance of reading the Medication Guide.
Urge patients to let you know promptly if they are still having trouble sleeping or experiencing other issues.
Be sure to discuss the importance of sleep hygiene and recommend an adequate trial period.